| Literature DB >> 32482354 |
Sule Arıcan1, Ramazan Dertli2, Suleyman Baktik3, Gulcin Hacibeyoglu4, Atilla Erol4, Sinan Oguzhan Ulukaya4, Esra Goger4, Özcan Erel5.
Abstract
BACKGROUND: The primary objective of this study was to investigate the effect of low dose ionizing radiation exposure on thiol/disulfide homeostasis and ischemia modified albumin levels. The secondary objective is to compare thiol/disulfide homeostasis and ischemia modified albumin levels among the personnel exposed to low dose ionizing radiation in anesthesia application areas, in and out of the Operation room.Entities:
Keywords: Albumina modificada por isquemia; Anestesia; Anesthesia; Ischemia modified albumin; Radiation; Radiação; Thiol; Tiol
Mesh:
Substances:
Year: 2020 PMID: 32482354 PMCID: PMC9373708 DOI: 10.1016/j.bjan.2020.02.009
Source DB: PubMed Journal: Braz J Anesthesiol ISSN: 0104-0014
Demographic, clinical features and laboratory primary outcomes of patients.
| Group exposed (n = 45) | Group control (n = 45) | 95% CI lower/upper | ||
|---|---|---|---|---|
| 36.11 ± 6.30 | 34.73 ± 6.59 | −1.32/4.07 | 0.314 | |
| 0.447 | ||||
| F | 8 (17.8%) | 12 (26.7%) | ||
| M | 37 (82.2%) | 33 (73.3%) | ||
| 73.25 ± 16.20 | 71.37 ± 12.68 | −4.89/6.67 | 0.592 | |
| 4.47 ± 0.53 | 5.32 ± 0.49 | −1.36/−0.62 | < 0.001 | |
| 0.76 ± 0.12 | 0.74 ± 0.08 | −0.02/0.06 | 0.457 | |
| 0.17 ± 0.04 | 0.14 ± 0.02 | 0.01/0.04 | < 0.001 | |
| 487.60 ± 62.91 | 541.41 ± 69.48 | −81.57/−26.03 | < 0.001 | |
| 556.64 ± 61.60 | 607.64 ± 71.36 | −78.92/−23.06 | < 0.001 | |
| 34.51 ± 7.82 | 33.11 ± 5.17 | −1.37/4.18 | 0.319 | |
| 7.24 ± 2.26 | 6.21 ± 1.35 | 0.24/1.80 | 0.011 | |
| 6.26 ± 1.61 | 5.50 ± 1.04 | 0.19/1.33 | 0.009 | |
| 87.46 ± 3.23 | 88.98 ± 2.08 | −2.66/−0.37 | 0.010 | |
IMA, Ischemia Modified Albumin; AU, Absorbance Units; IMAR, Ischemia Modified Albumin/Albumin.
Comparison of laboratory secondary outcomes of patients.
| Operation room (−) (n = 19) | Operation room (+) (n = 26) | 95% CI lower/upper | ||
|---|---|---|---|---|
| 37.10 ± 7.10 | 35.38 ± 5.67 | −2.12/5.56 | 0.372 | |
| 0.299 | ||||
| F | 5 (26.3%) | 3 (11.5%) | ||
| M | 14 (73.7) | 23 (88.5%) | ||
| 5.30 ± 2.40 | 6.61 ± 5.14 | −3.87/1.27 | 0.314 | |
| 4.41 ± 0.56 | 4.52 ± 0.52 | −0.44/0.21 | 0.502 | |
| 0.72 ± 0.10 | 0.79 ± 0.13 | −0.14/0.002 | 0.086 | |
| 0.16 ± 0.03 | 0.18 ± 0.04 | −0.03/0.01 | 0.418 | |
| 463 ± 56.96 | 505.0 ± 62.33 | −77.81/−4.59 | 0.028 | |
| 531.73 ± 54.13 | 574.85 ± 61.26 | −78.65/−7.57 | 0.019 | |
| 33.95 ± 10.16 | 34.92 ± 5.73 | −5.77/3.84 | 0.687 | |
| 7.51 ± 2.91 | 7.04 ± 1.68 | −0.91/1.85 | 0.499 | |
| 6.43 ± 2.04 | 6.14 ± 1.24 | −0.69/1.28 | 0.551 | |
| 87.12 ± 4.09 | 87.71 ± 2.49 | −2.57/1.39 | 0.551 | |
| 0.25 ± 0.06 | 0.21 ± 0.04 | 0.002/0.06 | 0.035 | |
| 0.29 ± 0.07 | 0.22 ± 0.04 | 0.02/0.09 | < 0.001 | |
| 0.63 ± 0.52 | 0.21 ± 0.04 | 0.21/0.62 | < 0.001 | |
| 0.70 ± 0.57 | 0.22 ± 0.04 | 0.24/0.70 | < 0.001 | |
IMA, Ischemia Modified Albumin; AU, Absorbance Units; IMAR, Ischemia Modified Albumin/Albumin; Hp 10, Personal dose equivalent for all body; Hp 0.07, Personal dose equivalent for skin; mSv, millisievert.
Figure 1ROC curves for serum IMAR, albumin concentrations to differentiate Exposed Group from the Control Group.
Figure 2ROC curves for serum native thiol, total thiol concentrations to differentiate Exposed Group from the Control Group.
ROC analysis.
| AUC | 95% CI | Sensitivity | 1 − Specificity | Cut-off | ||
|---|---|---|---|---|---|---|
| 0.879 | < 0.001 | 0.807–0.951 | 75.6 | 93.3 | 4.80 | |
| 0.717 | < 0.001 | 0.612–0.822 | 73.3 | 62.2 | 0.14 | |
| 0.731 | < 0.001 | 0.627–0.834 | 68.9 | 62.2 | 510 | |
| 0.717 | < 0.001 | 0.611–0.822 | 68.9 | 68.9 | 573 |
IMA, Ischemia Modified Albumin; IMAR, Ischemia Modified Albumin/Albumin; AUC, Area Under Curve; CI, Confidence Interval.